GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » Price-to-Owner-Earnings

Tenaya Therapeutics (Tenaya Therapeutics) Price-to-Owner-Earnings : (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-26), Tenaya Therapeutics's share price is $4.54. Tenaya Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Tenaya Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


TNYA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-26), Tenaya Therapeutics's share price is $4.54. Tenaya Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.64. Therefore, Tenaya Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-26), Tenaya Therapeutics's share price is $4.54. Tenaya Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.64. Therefore, Tenaya Therapeutics's PE Ratio without NRI for today is At Loss.


Tenaya Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Tenaya Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics Price-to-Owner-Earnings Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Tenaya Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tenaya Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Tenaya Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenaya Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's Price-to-Owner-Earnings falls into.



Tenaya Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Tenaya Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.54/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tenaya Therapeutics  (NAS:TNYA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Tenaya Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Executives
Timothy Hoey officer: Chief Scientific Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson officer: Chief Fin and Bus. Officer
Whittemore Tingley officer: Chief Medical Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali director, officer: Chief Executive Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava director C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019

Tenaya Therapeutics (Tenaya Therapeutics) Headlines

From GuruFocus

Tenaya Therapeutics Announces Pricing of Public Offering

By Value_Insider Value_Insider 11-17-2022

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

By sperokesalga sperokesalga 05-02-2023

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

By Stock market mentor Stock market mentor 02-07-2023

Tenaya Therapeutics Announces Proposed Public Offering

By Value_Insider Value_Insider 11-16-2022